Agios製藥 AGIO 深 滬
已收盤 04-02 16:00:00 美东时间
35.20
+1.010
+2.95%
華盛通- 最 高35.345
- 今 開33.97
- 成交量 142.55万股
- 最 低 33.5244
- 昨 收 34.19
- 總市值 20.62亿
- 52周最高 46.00
- 市盈率 靜 --
- 換手率 2.43%
- 52周最低 22.24
- 委 比 -80.67%
- 總股本 5859.22万
- 歷史最高 138.85
- 量 比 0.90
- 振 幅 5.32%
- 歷史最低 15.77
- 每 手 1
- 風險率 5.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?
.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.
04-01 00:39
Agios Pharmaceuticals Says It Will Pursue US Accelerated Approval For Mitapivat For Sickle Cell Disease
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue U.S. accelerated
03-31 19:05
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $65
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $62 to $65.
02-13 03:01
财报速睇 | Agios制药 2025财年Q4营收0.20亿美元，同比增长86.9%；归母净利润亏损1.08亿美元，同比亏损扩大11.9%
华盛资讯2月12日讯，Agios制药公布2025财年Q4业绩，公司Q4营收0.20亿美元，同比增长86.9%，归母净利润亏损1.08亿美元，同比亏损扩大11.9%。
02-12 19:49
Earnings Summary: Agios Pharmaceuticals Q4
The earnings results for Agios Pharmaceuticals (NASDAQ:AGIO) for Q4 were made p...
02-12 19:36
Agios Pharmaceuticals Q4 EPS $(1.86) Beats $(1.94) Estimate, Sales $19.967M Beat $12.014M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(1.94) by 3.93 percent. This is a 4.12 percent increase over losses of $(1.94) per share
02-12 19:35
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
